Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

@article{Bresalier2005CardiovascularEA,
  title={Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.},
  author={R. Bresalier and R. Sandler and H. Quan and J. Bolognese and B. Oxenius and K. Horgan and C. Lines and R. Riddell and D. Morton and {\'A}. Lanas and M. Konstam and J. Baron},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 11},
  pages={
          1092-102
        }
}
BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of… Expand

Paper Mentions

Interventional Clinical Trial
This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside… Expand
ConditionsColorectal Adenoma
InterventionDrug
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
COX 2 inhibitors, traditional NSAIDs, and the heart
Relative Thromboembolic Risks Associated with COX-2 Inhibitors
  • S. Jones
  • Medicine
  • The Annals of pharmacotherapy
  • 2005
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
...
1
2
3
4
...